News | April 11, 2025
Granules India completes acquisition of Senn Chemicals
Strengthening capabilities in Peptide Therapeutics and CDMO services
Strengthening capabilities in Peptide Therapeutics and CDMO services
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Granules now has a total of 67 ANDA approvals from the USFDA
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
_256_384.jpg)
This facility manufactures APIs & formulations of oncology and non-oncology products.
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
Subscribe To Our Newsletter & Stay Updated
